Analysis of correlation between plasma trough level and response of generic imatinib in the treatment of Chinese patients with chronic myeloid leukemia.
10.3760/cma.j.issn.0253-2727.2019.11.010
- Author:
Jian Hua YOU
1
;
Juan CHEN
;
Li ZHOU
;
Sheng Hong DU
;
Hong Ying LU
;
Shu Jun SUN
;
Jun Min LI
;
Zhi Xiang SHEN
Author Information
1. Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
- Publication Type:Journal Article
- Keywords:
Imatinib;
Leukemia, myeloid, chronic;
Plasma trough level
- MeSH:
Antineoplastic Agents;
Humans;
Imatinib Mesylate/therapeutic use*;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Treatment Outcome
- From:
Chinese Journal of Hematology
2019;40(11):939-942
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the correlation between plasma trough level of generic imatinib and its metabolism and clinical outcomes in Chinese patients with chronic myeloid leukemia in chronic phase (CML-CP) . Methods: The 21 patients with CML-CP who enrolled in a clinical trial YMTN 1.0 from Oct 11(th), 2012 to May 8(th), 2013 and received generic imatinib were as study subjects. The correlation between steady plasma trough levels of imatinib and its metabolism with clinical response, age, weight and body surface area (BSA) were evaluated. Results: ①The mean steady plasma trough level of generic imatinib and its metabolism was (1 185.07±417.91) μg/L and (251.53±76.50) μg/L, respectively. ②Age, weight and BSA has no significant effects on plasma trough level of generic imatinib and its metabolism (P>0.05) . ③Patients with steady plasma trough level of generic imatinib more than 1 000 μg/L are possible to have higher major molecular response (MMR) /complete molecular response (CMR) rate than those below 1 000 μg/L (42% vs 0, P<0.05) . Conclusion: Plasma trough levels of generic imatinib varied in CML patients. The steady plasma trough levels of generic imatinib is maybe related to molecular response in CML patients.
